Is There Hope for Advanced Gastric Cancer? This CAR-T Therapy Might Be Right for You
Immunofoco
Developer of Novel Therapeutics for Solid Tumors
Gastric cancer is a common malignant tumor of the digestive tract in China, with consistently high incidence and mortality rates. Due to the hidden early symptoms, many patients are diagnosed at an advanced stage, losing the opportunity for surgical cure. In the traditional treatment system, surgery, chemotherapy, and radiotherapy are the main methods, but for patients whose condition continues to progress after multiple lines of treatment, effective treatment options are very limited, and the prognosis is generally poor.
Recently, the national investigators' meeting for "A multicenter, randomized, controlled, open-label Phase III confirmatory clinical study comparing IMC002 with investigator's choice of treatment in adult subjects with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing CLDN18.2 who have received at least two prior lines of therapy and are not candidates for surgery," hosted by Immunofoco, was successfully held. This brings new treatment opportunities for patients with this type of advanced gastric cancer and marks a critical phase in the clinical research of CAR-T therapy targeting CLDN18.2.
CAR-T Therapy: A New Hope for Patients with Advanced Gastric Cancer
With the continuous development of medical technology, breakthrough progress has been made in the field of cellular immunotherapy, among which CAR-T cell therapy has brought new hope to patients with advanced gastric cancer.
The principle of CAR-T cell therapy is not complicated. In simple terms, it involves "upgrading" the patient's own immune T cells. First, doctors collect some healthy T cells from the patient’s body. Then, in the lab, genetic engineering technology is used to equip these T cells with a special "navigation" system — chimeric antigen receptor (CAR). This CAR can accurately identify specific antigens on the surface of tumor cells, essentially providing the T cells with "precise navigation" that allows them to locate cancer cells in the body accurately. Finally, the modified CAR-T cells are cultured and expanded before being infused back into the patient’s body. These fully "equipped" CAR-T cells, guided by their "navigation," can precisely find and attack cancer cells, thereby achieving the goal of treating tumors.
Compared with traditional treatment methods, CAR-T therapy has the advantages of high precision and strong targeting, which can reduce damage to normal cells while more effectively killing tumor cells, bringing new treatment possibilities for patients with advanced gastric cancer.
1. IMC002 Clinical Trial CR Case: Highlights Product Clinical Potential
This conference brings together clinical experts, institutional and ethical representatives from more than thirty participating centers across China, as well as the collaborating teams, to engage in an in-depth discussion on the efficacy and safety of IMC002 in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma. The aim is to promote the comprehensive launch of high-quality clinical research and patient enrollment, allowing more eligible patients the opportunity to access this potential treatment option.
At the conference, Dr. Lin Xiuyun from Fujian Cancer Hospital shared a case that achieved sustained complete remission (CR). The patient, who had advanced HER2-positive gastric cancer with liver metastasis, experienced continuous disease progression after multiple lines of targeted immunotherapy and chemotherapy, and HER2 expression turned negative, leaving very limited subsequent treatment options. After enrolling in the IMC002 clinical trial and receiving a single infusion of IMC002, the patient achieved sustained complete remission (CR) at the 10-month mark. Following enrollment and treatment, the patient did not receive any other anti-tumor therapies. The efficacy improved from partial remission (PR) to complete remission (CR), with both endoscopic diagnosis and gastroscopic biopsy showing pathologically negative results, and quality of life significantly improved. Recent tumor assessment one year post-infusion showed continued complete remission.
2. National expert consensus clearly defined, jointly promoting high-quality clinical enrollment
Prof. Xu Jianming, the national leading principal investigator from the First Medical Center of Chinese PLA General Hospital, fully affirmed the positive data from the preliminary study of IMC002 and emphasized the significant importance of this clinical project in meeting patient needs. As the leading expert, Prof. Xu Jianming stated that he will collaborate with all participating centers to strictly implement the study protocol, ensuring the compliance of the clinical trial and the scientific integrity of the data, jointly promoting the high-quality development of China's cell therapy field.
The successful convening of this launch meeting marks that the IMC002-RT02-RCT Phase III confirmatory clinical study has officially entered a new stage of comprehensive acceleration, which will provide strong momentum for the smooth progress of the study and rapid patient enrollment. The following are some clinical centers participating in this Phase III confirmatory clinical study:
If you or someone around you is a patient with advanced gastric cancer who meets the enrollment criteria for the IMC002 Phase III clinical study and would like to learn more about the study details or confirm eligibility, you can add the WeChat assistant below for consultation. The assistant will provide one-on-one information support, help you connect with relevant clinical centers, and assist patients in accessing potential treatment opportunities promptly.
Editorial Responsibility: zane
Typesetting Editor: Zane
